The document discusses selective estrogen receptor modulators (SERMs), which are designed to act in tissue-specific ways at estrogen receptor sites. Ormeloxifene is presented as a potential ideal SERM due to its varied tissue responses. It has antagonistic effects in the uterus and breast but mild estrogenic effects on bone, brain, and lipids. Ormeloxifene is currently approved to treat dysfunctional uterine bleeding and is being evaluated for additional uses like breast cancer prevention and treatment. However, more clinical trials are still needed before it can be introduced internationally.